Viewing Study NCT06597565



Ignite Creation Date: 2024-10-26 @ 3:40 PM
Last Modification Date: 2024-10-26 @ 3:40 PM
Study NCT ID: NCT06597565
Status: RECRUITING
Last Update Posted: None
First Post: 2024-09-12

Brief Title: A Phase II Study of ACR-368 and Low Dose Gemcitabine in RM HNSCC
Sponsor: None
Organization: None

Study Overview

Official Title: A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent andor Metastatic Head and Neck Squamous Cell Carcinoma
Status: RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to determine the activity and safety of ACR-368 prexasertib in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma HNSCC Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None